Giant cell arteritis (GCA) can be classified into Cranial(C)-GCA and Large Vessel(LV)-GCA. Based on analysis of temporal arteries, GCA is postulated to be T-cell-mediated. Recently, a disturbed B-cell homeostasis was documented in newly diagnosed GCA patients. In the current study, we assessed the presence of B-cells and their level of ectopic organization in the aorta of LV-GCA patients. Aorta tissue samples of 9 histologically-proven LV-GCA patients and 22 age- and sex-matched atherosclerosis patients who underwent aortic aneurysm surgery were studied by immunohistochemistry. Sections were stained for B-cells, T-cells, follicular dendritic cells, high endothelial venules, germinal center B-cells, proliferating B-cells, macrophages, and plasma cells. Aortas of LV-GCA patients showed massive infiltration of B-cells, which clearly outnumbered T-cells, as opposed to C-GCA patients where, as previously reported, T-cells outnumber B-cells. B-cells were mainly found in the adventitia of the vessel wall and were organized into artery tertiary lymphoid organs. These tertiary lymphoid organs had germinal centers, proliferating B-cells and plasma cell niches. In conclusion, we found massive and organized B-cell infiltrates in the aorta of LV-GCA patients, which is in line with the previously documented decrease of circulating B-cells in active GCA. Our data indicate a role for B-cells in the pathogenesis of GCA and thus evoke further investigation into the factors determining the tissue tropism and organization of B-cells in GCA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361817PMC
http://dx.doi.org/10.3389/fimmu.2019.00083DOI Listing

Publication Analysis

Top Keywords

lv-gca patients
16
tertiary lymphoid
12
lymphoid organs
12
b-cells
11
artery tertiary
8
giant cell
8
cell arteritis
8
aorta lv-gca
8
proliferating b-cells
8
patients
7

Similar Publications

Background: Takayasu arteritis (TAK) and giant cell arteritis (GCA), the most common forms of large-vessel vasculitis (LVV), can result in serious morbidity. Understanding the molecular basis of LVV should aid in developing better biomarkers and treatments.

Methods: Plasma proteomic profiling of 184 proteins was performed in two cohorts.

View Article and Find Full Text PDF

Objectives: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischaemic complications (IC) in giant cell arteritis (GCA).

Methods: Retrospective observational analysis of GCA clinically confirmed patients referred to US fast-track clinics at two centres. All patients underwent baseline US of cranial and extracranial arteries (carotid, subclavian and axillary).

View Article and Find Full Text PDF

Giant cell arteritis (GCA) is an autoimmune/autoinflammatory disease affecting large vessels in patients over 50 years old. The disease presents as an acute inflammatory response with two phenotypes, cranial GCA and large-vessel vasculitis (LV)-GCA, involving the thoracic aorta and its branches. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET-CT) is among the imaging techniques contributing to diagnosing patients with systemic disease.

View Article and Find Full Text PDF

Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases.

Reumatismo

October 2024

Division of Rheumatology, "La Colletta" Hospital, Azienda Sociosanitaria Ligure 3, Arenzano.

Article Synopsis
  • This case series evaluates the effectiveness and safety of baricitinib (BARI) in treating six patients suffering from polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), particularly when traditional treatments like tocilizumab were unavailable.
  • Patients showed significant improvement in symptoms, with a notable reduction in their disease activity scores and the ability of some to discontinue glucocorticoids while on BARI.
  • Overall, the findings align with previous studies indicating that Janus kinase inhibitors may serve as a helpful alternative for managing PMR and GCA by reducing reliance on glucocorticoids, although one patient did experience pneumonia after treatment.
View Article and Find Full Text PDF

Objectives: To assess the maintenance of efficacy of one year of tocilizumab (TCZ) monotherapy after its discontinuation in large vessel-GCA (LV-GCA).

Methods: 17 patients with active LV-GCA were previously treated with 3 boluses of intravenous methylprednisone and weekly subcutaneous TCZ in monotherapy for 52 weeks. Patients in relapse-free clinical remission at week 52 discontinued TCZ and entered part two, which was a 26-week observational follow-up period.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!